Eli Lilly and Company

Key Updates

Eli Lilly declined 2.51% to $911.60 since the last report, extending losses below the $935 support level and marking a YTD decline of 15.17%. The downward momentum intensified following HSBC's rare downgrade to Reduce with an $850 price target, representing the first major sell rating amid concerns about obesity market sustainability and pricing pressures. This downgrade triggered a 4% single-day decline on March 17th, making LLY the worst S&P 500 performer that day. The stock now trades significantly below its recent $970-$1,000 support zone, with the selloff accelerating despite positive operational developments including the Employer Connect platform launch and AI-driven manufacturing improvements.

Current Trend

LLY has entered a pronounced downtrend with YTD losses of 15.17%, contrasting sharply with the 19.49% gain over six months. The stock has broken through multiple support levels, declining 12.35% over the past month and 8.83% over five days. The current price of $911.60 represents a significant retreat from previous resistance levels near $1,000, with the recent HSBC downgrade catalyzing accelerated selling pressure. Technical deterioration is evident as the stock failed to hold the $935 level established in the previous report, suggesting further downside risk toward the $850 target cited by HSBC. The sharp reversal from six-month gains indicates a fundamental reassessment of valuation multiples and growth expectations for the obesity franchise.

Investment Thesis

The investment thesis centers on Lilly's dominant position in the GLP-1 obesity and diabetes market, with Mounjaro and Zepbound generating $36.5 billion in combined 2024 revenue (56% of total sales). The company's competitive advantages include superior clinical efficacy (20.9% weight loss versus competitors), AI-enhanced manufacturing capabilities that resolved supply constraints, and strategic market expansion through the Employer Connect platform targeting 100 million American adults with obesity. However, the thesis faces material challenges from HSBC's reduced peak market forecast of $80-120 billion by 2032 (versus consensus $150 billion by 2030), intensifying pricing competition, and concerns about the sustainability of cash-pay models amid potential economic pressures. The upcoming oral GLP-1 Orforglipron represents a critical pipeline catalyst, though analysts question whether pills can match injection efficacy.

Thesis Status

The investment thesis is under significant pressure as market expectations recalibrate. While operational execution remains strong—with AI-driven production increases, successful platform launches, and maintained 25% revenue growth guidance for 2026—the valuation premium has become vulnerable to downward revisions. HSBC's downgrade explicitly challenges the "priced to perfection" narrative, noting that Lilly gained 20% over the past year while rival Novo Nordisk fell 55%. The $80-120 billion peak market estimate represents a 33-47% reduction from consensus, directly undermining long-term growth projections. The thesis remains intact regarding product superiority and market leadership, but faces headwinds from pricing pressure, competitive intensity, and macroeconomic concerns about middle-class affordability of $299-449 monthly treatments. The contrast between strong operational metrics and deteriorating stock performance suggests investors are discounting future margin compression and market saturation risks.

Key Drivers

The primary catalyst driving current weakness is HSBC's downgrade to Reduce with an $850 target, representing a rare sell rating that questions obesity market size assumptions and highlights pricing competition risks. This downgrade follows Novo Nordisk's 55% decline, raising concerns about sector-wide valuation compression. Positively, Lilly launched its Employer Connect platform with over fifteen partners, offering Zepbound at $449 across all doses to address the coverage gap affecting half of commercially insured employees. The company's AI-driven manufacturing improvements materially increased GLP-1 production, with Mounjaro doubling revenue to $23 billion and Zepbound surging to $13.5 billion in 2024. However, concerns persist about cash-pay sustainability given potential AI-driven job losses affecting middle-class affordability, and questions remain about oral GLP-1 efficacy versus injections.

Technical Analysis

LLY exhibits clear bearish momentum with the stock breaking below the $935 support level to trade at $911.60, down 2.51% since the last report. The five-day decline of 8.83% and one-month drop of 12.35% indicate accelerating selling pressure following the HSBC downgrade. The stock has surrendered the critical $970-$1,000 support zone that provided stability in previous reports, with the current level approaching HSBC's $850 price target. The YTD decline of 15.17% contrasts sharply with the six-month gain of 19.49%, suggesting a significant trend reversal beginning in 2026. Key resistance now sits at $935-$950, with further downside risk toward $850 if selling pressure persists. The technical breakdown coincides with deteriorating sentiment, as evidenced by LLY becoming the worst S&P 500 performer on the downgrade day. Volume patterns suggest institutional repositioning following the valuation reassessment.

Bull Case

• Dominant GLP-1 franchise with superior clinical efficacy: Zepbound was the most prescribed weight management medication in 2025, with clinical data showing 20.9% body weight loss at 15mg dose, supporting premium pricing and market share gains. Source
• AI-enhanced manufacturing driving material production increases: Digital twin technology optimized manufacturing processes sufficiently to impact earnings reports, with Mounjaro revenue doubling to $23 billion and Zepbound surging to $13.5 billion in 2024, representing 56% of total revenue. Source
• Employer Connect platform expands addressable market: Partnership with over fifteen administrators targets the 50% of commercially insured employees lacking obesity coverage, with Zepbound offered at $449 across all doses, addressing a $1.7 trillion annual economic burden. Source
• Strong revenue growth guidance maintained: Lilly forecasts 25% revenue growth in 2026, significantly outpacing rival Novo Nordisk's projected 5-13% decline, indicating sustained competitive advantage and market share gains. Source
• Market leadership position with 20% stock appreciation: Lilly gained 20% over the past year while Novo Nordisk fell 55%, demonstrating relative strength and becoming the first healthcare company to reach $1 trillion market capitalization in late 2024. Source

Bear Case

• HSBC downgrade challenges market size assumptions with $850 target: Analysts reduced peak obesity market forecast to $80-120 billion by 2032 versus consensus $150 billion by 2030, citing overhyped expectations and intensifying pricing competition, with stock "priced to perfection." Source
• Cash-pay model sustainability concerns amid economic pressures: Middle-class Americans paying $299-449 monthly out-of-pocket face potential job losses from AI disruption, questioning long-term demand sustainability for non-insurance reimbursed treatments. Source
• Competitive pricing pressure expected to intensify: HSBC warns that pricing competition from Novo Nordisk and other entrants will likely compress margins, with the market potentially becoming commoditized as supply constraints ease industry-wide. Source
• Questions about oral GLP-1 efficacy versus injections: Analysts express skepticism about whether the upcoming Orforglipron pill can match injection effectiveness, potentially limiting the addressable market expansion and competitive differentiation. Source
• Novo Nordisk struggles signal sector-wide risks: Competitor's 55% decline and projected revenue contraction serve as a warning for potential Lilly performance deterioration, with HSBC recommending AstraZeneca, AbbVie, and Johnson & Johnson as better healthcare alternatives. Source